Physician profile
Simon N Parkinson
NPI 1114990371
$40,228.88
in general payments reported to CMS, 2019-2025
71 companies · $9,848 in 2025
The $9,848 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $8,791 · 2022: $4,952 · 2023: $7,500 · 2024: $9,138 · 2025: $9,848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Travel and Lodging: $3,199 · Education: $339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,897.47 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,051.32 |
| Travel and Lodging | $3,198.60 |
| Education | $338.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $22,586.51 | 2021-2025 | |
| Ipsen Innovation | $3,885.55 | 2024-2025 | |
| Allergan, INC. | $1,040.90 | 2021-2022 | |
| Biogen, INC. | $1,020.01 | 2021-2025 | Tysabri, Vumerity, Tysabri |
| Pfizer INC. | $972.17 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $831.70 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $730.87 | 2021-2025 | |
| Ucb, INC. | $657.19 | 2021-2025 | Briviact, Fintepla, Nayzilam |
| Csl Behring | $617.86 | 2021-2025 | Hizentra, Privigen |
| Teva Pharmaceuticals USA, INC. | $473.83 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Lilly USA, LLC | $467.29 | 2021-2025 | Emgality, Reyvow, Amyvid |
| Axsome Therapeutics, INC. | $459.23 | 2024-2025 | Symbravo, Sunosi |
| Genzyme Corporation | $435.84 | 2021-2023 | |
| Eisai INC. | $421.45 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $398.61 | 2021-2025 | Ultomiris |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $354.35 | 2021-2025 | Vyepti |
| Celgene Corporation | $335.13 | 2023-2025 | Zeposia |
| Emd Serono, INC. | $317.01 | 2022-2025 | Mavenclad |
| Neurocrine Biosciences, INC. | $253.82 | 2022-2025 | Ingrezza, Ongentys |
| Otsuka America Pharmaceutical, INC. | $214.95 | 2023-2025 | Rexulti |
| Argenx US, INC. | $211.63 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Amneal Pharmaceuticals LLC | $210.98 | 2021-2025 | Rytary, Crexont |
| Sunovion Pharmaceuticals INC. | $203.41 | 2021-2022 | |
| Genentech USA, INC. | $184.06 | 2023-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Acorda Therapeutics, INC | $181.03 | 2022-2023 | Inbrija, Ampyra |
| Biohaven Pharmaceuticals, INC. | $167.25 | 2021 | |
| Sk Life Science, INC. | $161.36 | 2021-2023 | |
| Ipsen Biopharmaceuticals, INC | $149.02 | 2025 | Dysport |
| Grifols USA, LLC | $148.62 | 2022-2025 | Gamunex-C |
| Neurelis, INC. | $143.17 | 2022-2025 | Valtoco |
| Merz Pharmaceuticals, LLC | $130.60 | 2024-2025 | Xeomin, Inbrija |
| Upsher-Smith Laboratories LLC | $118.78 | 2021-2023 | |
| Scilex Pharmaceuticals INC. | $100.35 | 2023-2024 | Ztlido |
| Astrazeneca Pharmaceuticals LP | $95.82 | 2025 | Wainua |
| Impel Pharmaceuticals INC. | $95.72 | 2023 | Trudhesa |
| Mallinckrodt Hospital Products INC. | $87.18 | 2024-2025 | Acthar |
| Avadel Cns Pharmaceuticals, LLC | $82.89 | 2024-2025 | Lumryz |
| Acadia Pharmaceuticals INC | $77.72 | 2024-2025 | Nuplazid |
| Supernus Pharmaceuticals, INC. | $70.48 | 2021-2022 | |
| Amgen INC. | $63.20 | 2021-2024 | Uplizna |
| Alnylam Pharmaceuticals INC. | $62.84 | 2023 | Givlaari, Amvuttra |
| Insightec,INC | $61.33 | 2023 | Exablate |
| Octapharma USA, INC. | $58.41 | 2024 | Panzyga, Cutaquig |
| Avion Pharmaceuticals | $57.49 | 2022 | |
| Inspire Medical Systems, INC. | $48.12 | 2024 | Inspire |
| Cycle Pharmaceuticals INC | $46.88 | 2025 | Bafiertam, Tascenso Odt |
| Abbott Laboratories | $46.26 | 2024-2025 | Eterna, Amplatzer Talisman |
| Azurity Pharmaceuticals, INC. | $45.13 | 2024 | Horizant |
| Horizon Therapeutics Plc | $44.68 | 2021-2023 | Uplizna |
| Ani Pharmaceuticals, INC. | $43.89 | 2023-2024 | Purified Cortrophin Gel |
| Biohaven Pharmaceutical Holding Company LTD. | $43.56 | 2022 | |
| Sumitomo Pharma America, INC. | $43.10 | 2023 | Aptiom |
| Tanabe Pharma America, INC. | $42.90 | 2023-2024 | |
| Ge Healthcare | $37.98 | 2024-2025 | |
| Banner Life Sciences, LLC | $37.83 | 2023 | |
| Idorsia Pharmaceuticals US INC | $30.75 | 2023 | Quviviq |
| Averitas Pharma INC. | $30.32 | 2024 | Qutenza |
| Collegium Pharmaceutical, INC. | $29.33 | 2022 | |
| Vanda Pharmaceuticals INC. | $26.28 | 2025 | Ponvory |
| Otto Bock Healthcare LP | $23.99 | 2023 | |
| Corium, LLC | $21.76 | 2023 | Adlarity |
| Tg Therapeutics, INC. | $21.28 | 2023 | |
| Harmony Biosciences LLC | $21.15 | 2023 | Wakix |
| Avanir Pharmaceuticals, INC. | $20.55 | 2022 | |
| Mdd US Operations, LLC | $20.07 | 2025 | |
| Boston Scientific Corporation | $19.64 | 2025 | General - Pain Management |
| Kyowa Kirin, INC. | $19.41 | 2025 | |
| Livanova USA, INC. | $18.96 | 2021 | |
| Impel Pharmaceuticals LLC | $17.02 | 2025 | Trudhesa |
| Tonix Medicines, INC. | $16.32 | 2025 | Zembrace Symtouch |
| C2n Diagnostics, LLC | $14.11 | 2025 | Precivityad2 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Parkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.